Abstract
Autoimmunity has both beneficial and harmful aspects. Beneficial aspects include: (1) removal of released intracytoplasmic antigens (ags) (cells at the end of their life span or damaged by outside agents) by specific nonpathogenic IgM autoantibodies and mononuclear cells and (2) recognition and elimination of cancerous cells. In contrast, harmful aspects include: (1) mounting a pathogenic autoimmune response against a tissue-derived ag, a ‘modified self,’ resulting in autoimmune disease and (2) inability to recognize and eliminate a cancerous clone. The immune system continuously faces internal and external influences; however, even when it is compromised or overwhelmed, it will still endeavor to regain and maintain tolerance to self. To promote this, we developed a ‘modified vaccination technique’ (MVT) (described as the third vaccination method after active and passive immunizations). It has two components: purified exogenous/endogenous ag (i.e., target ag) and a high-titer-specific antibody (ab) against the target ag made into an immune complex (IC) with predetermined immune-inducing components. The MVT works by ab information transfer (production of same class of immunoglobulin with the same specificity against the target ag that is present in the vaccine), thereby re-establishing tolerance to self (caused by exogenous/endogenous ags) following repeated administration of appropriate ICs. This vaccination technique can be used both prophylactically and therapeutically, and it mimics the immune system’s natural abilities to respond to corrective information specifically, rapidly, safely and with minimal side effects and makes this approach a novel solution for many disorders that are difficult or impossible to cure or manage.
Similar content being viewed by others
Abbreviations
- aab:
-
Autoantibody
- aag:
-
Autoantigen
- ab:
-
Antibody
- ag:
-
Antigen
- BB:
-
Brush border
- HN:
-
Heymann nephritis
- IC:
-
Immune complex
- MM:
-
Multiple myeloma
- MVT:
-
Modified vaccination technique
- rKF3:
-
Rat kidney fraction 3
- rarKF3:
-
Rat anti-rat kidney fraction 3
References
Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol. 1966;1(4):433–42.
Weir DM, Elson CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum. 1969;12(3):254–60.
Weir DM, Pinckard RN. Failure to induce tolerance to rat tissue antigens. Immunology. 1967;13(4):373–80.
Weir DM. The immune response after tissue injury. Pathol Eur. 1966;1(1):108–18.
Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol. 2003;84(6):245–58.
Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol. 2004;85(5):277–85.
Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med. 1996;100(3):299–308.
Soldan SS, Jacobson S. Infection and multiple sclerosis. In: Shoenfeld Y, Rosenzweig LJ, editors. Infection and autoimmunity. Amsterdam: Elsevier; 2004. p. 559–82.
Totoritis MC, Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med. 1985;78(3):149–61.
Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001;108(8):1097–104.
Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin N Am. 1994;20(1):61–86.
Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA. 2000;97(3):1184–9.
Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol. 2005;35(1):252–60.
Wermeling F, Karlsson MC, McGaha TL. An anatomical view on macrophages in tolerance. Autoimmun Rev. 2009;9(1):49–52.
Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 2005;26(4):425–32.
Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005;38(4):259–64.
Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today. 1991;12(5):154–9.
Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity. 2004;37(2):95–102.
Blank M, Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun. 2007;28(2–3):62–8.
Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17(3):791–5.
Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5(8):433–41.
Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100.
Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005;4(8):526–31.
Rommer PS, Dudesek A, Stuve O, Zettl UK. Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol. 2014;175(3):373–84.
Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83.
Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol. 2004;85(6):321–34.
Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev. 2005;4(8):565–70.
Barabas AZ, Cole CD, Lafreniere R, Weir DM. Regaining tolerance to a self-antigen by the modified vaccination technique. Clin Rev Allergy Immunol. 2013;45(2):193–201.
Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun. 2010;34(3):J287–99.
Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J. 2007;6(4):12–8.
Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol. 2010;71(3):125–33.
Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005;435(7042):612–9.
Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25(6):862–75.
Pani A. Standard immunosuppressive therapy of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):848–53.
Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44(3):385–401.
Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R. Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit. 2007;13(5):BR119–24.
Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, et al. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci. 2009;14:3892–8.
Barabas AZ, Cole CD, Sensen M, Lafreniere R. Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol. 2012;93(1):11–7.
Mackay IR. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev. 2010;9(5):A251–8.
Selmi C. Autoimmunity in 2012. Clin Rev Allergy Immunol. 2013;45(2):290–301.
Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol. 2009;70(6):516–25.
Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev. 2009;8(7):552–7.
Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637–43.
Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med. 1959;100:660–4.
Barabas AZ, Cole CD, Barabas AD, Cowan JM, Yoon CS, Waisman DM, et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol. 2004;85(4):201–12.
Barabas AZ, Cole CD, Lafreniere R, Weir DM. Implicated autoantibodies in a kidney disease. In: Jenkins GE, Hall JI, editors. Autoantibodies: detection, pathogenicity and health implications. Hauppauge: Nova Science Publishers, Inc; 2012. p. 1–36.
Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S. Formation of immune deposits and disease. Lab Invest. 1986;55(5):510–20.
Cameron JS. Membranous nephropathy–still a treatment dilemma. N Engl J Med. 1992;327(9):638–9.
Ronco P, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol. 2006;17(7):1772–4.
Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int. 2006;56(4):181–90.
Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010;16(7):799–803.
von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.
Kabe KL, Kolesar JM. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm. 2006;63(6):527–33.
Munshi C, Aarhus R, Graeff R, Walseth TF, Levitt D, Lee HC. Identification of the enzymatic active site of CD38 by site-directed mutagenesis. J Biol Chem. 2000;275(28):21566–71.
Munshi CB, Fryxell KB, Lee HC, Branton WD. Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol. 1997;280:318–30.
Acknowledgments
This work was supported by a Grant from an anonymous donor. All authors have contributed to, critically reviewed and approved this article. None of the authors has any conflict of interest to declare. We acknowledge the assistance of our research associate, Zoltan Kovacs, in computer and laboratory-related work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barabas, A.Z., Cole, C.D., Graeff, R.M. et al. Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events. Immunol Res 65, 402–409 (2017). https://doi.org/10.1007/s12026-016-8842-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-016-8842-6